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Objective: To describe the approach used to promote adherence to antiretroviral
therapy (ART) and to present the outcomes in the ﬁrst primary care public sector ART
project in South Africa.
Design: The study is a prospective open cohort, including all adult patients naive to
previous ART who received antiretroviral treatment in Khayelitsha, from May 2001 to
the end of 2002. Patients were followed until their most recent visit before 31 July 2003.
Methods: Plasma viral load was determined at 3, 6, 12, 18 and 24 months after ART
was initiated, and CD4 cell counts 6-monthly. Kaplan–Meier estimates were deter-
mined for the cumulative proportions of patients surviving, and patients with viral load
suppression and viral rebound.
Results: A total of 287 patients were initiated on triple therapy. The probability of
survival was 86.3% at 24 months. The median CD4 cell count gain was 288 cells/la t
24 months. Viral load was less than 400 copies/ml in 89.2, 84.2 and 69.7% of patients
at 6, 12 and 24 months, respectively. The cumulative probability of viral rebound (two
consecutive HIV-RNA measurements above 400 copies/ml) after achieving an HIV-
RNA measurement below 400 copies/ml was 13.2% at 18 months.
Conclusion: The study shows that, with a standard approach to patient preparation
and strategies to enhance adherence, a cohort of patients on ART can be retained in a
resource-limited setting in a developing country. A high proportion of patients
achieved suppression of viral replication. The subsequent probability of viral rebound
was low. & 2004 Lippincott Williams & Wilkins
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Introduction
In rich countries the use of antiretroviral therapy
(ART) has signiﬁcantly reduced the morbidity and
mortality of patients who are infected with HIV [1].
Although many have claimed that the use of ART in
resource-limited settings such as in sub-Saharan Africa
is not feasible because of the complexity of ART and
the alleged inability of poor individuals to adhere to
lifelong therapy, projects in these countries have
demonstrated that treatment programmes can achieve
adherence rates comparable to those described in
wealthier, developed countries with smaller epidemics
[2,3].
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essential, and remain a key challenge, especially when
considering the target of reaching the large numbers of
individuals who are in need of ART. Methods used to
enhance adherence in the primary care setting have not
been well described. The objectives of this paper are to
describe the approach used to promote adherence and
to present the outcomes in the ﬁrst primary care public
sector ART project in South Africa.
Setting
Khayelitsha is a township in Cape Town, with a
population of 400 000. The HIV-1 seroprevalence in
public-sector antenatal clinics in this health district in
2002 was 24.9% [4]. There is widespread poverty, and
unemployment levels are extremely high. Most resi-
dents rely on health services delivered by the state. In
April 2000, the provincial health department concluded
an agreement with Me ´decins Sans Frontie `res (MSF), to
open services for patients with HIV-related illnesses
within three community health centres in Khayelitsha.
MSF started providing ART in May 2001. MSF pays
for the antiretroviral medication, the viral load meas-
urements and half of the staff, whereas the provincial
department of health pays for other expenses.
Clinical services are provided by a doctor–nurse–
counsellor team in each of the three clinics. The teams
currently consist of one doctor, two nurses and two
counsellors. At the end of 2002, the clinics were
managing 250 adults and 50 children on ART, and had
accumulated a combined client base of 4500 patients.
An additional 25 patients were being placed on ART
each month.
Only patients who attended the HIV clinic regularly
and who lived in Khayelitsha were considered for
ART. Clinical, biological, adherence and social criteria
had to be fulﬁlled in order for patients to be eligible for
ART. Only patients in stages III or IV according to the
World Health Organization classiﬁcation and who had
also a CD4 cell count of less than 200 cells/l were
eligible on clinical grounds. Regular clinic attendance
and previous adherence to co-trimoxazole prophylaxis
and tuberculosis treatment were used to assess the
ability to adhere to ART. All patients were visited at
home before starting ART to verify their residence,
disclosure to at least one individual and to assess
support structures. A community selection committee
reviewed clinical and non-clinical eligibility criteria.
Patient preparation after selection involved three struc-
tured individual counselling sessions.
A patient-centred preparation programme supported
adherence to ART. Patients were enrolled into com-
prehensive HIV care, and developed relationships with
the care team well before starting ART. The adherence
promotion programme consisted of three components.
Trained counsellors were available during clinic hours
to assist and support individual patients having difﬁcul-
ties with any aspect of ART. All patients were requested
to identify a ‘treatment assistant’, usually someone living
in their household, who could assist them with adher-
ence issues. The treatment assistant signed the consent
to start treatment together with the patient. Homes
were visited as required for a more thorough follow-up
of those patients with speciﬁc problems.
Peer support groups exclusively for patients on ART
facilitated discussions on factors that enhanced or were
barriers to adherence, adverse events, disclosure and
other psychosocial issues, and also served as forums for
health promotion and education.
Material support such as pillboxes, drug identiﬁcation
charts, daily schedules, diaries and educational materials
were provided and explained the schedules, risks and
beneﬁts of ART. A treatment access non-governmental
organization (Treatment Action Campaign) was active
in the area, and contributed to the treatment literacy of
patients and an understanding of the mode of action of
ART.
Standard triple therapy regimens were used. First-line
therapy included zidovudine, lamivudine and nevira-
pine or efavirenz.
All patients on ART were assessed biologically accord-
ing to a standard schedule. Plasma viral load measure-
ments were conducted before initiating ART and
repeated at 3 and 6 months’ duration on ART and
then 6-monthly thereafter. CD4 cell counts were
conducted 6-monthly after the initiation of ART.
A standard approach has been developed for dealing
with viral rebound. When the ﬁrst level above 400
copies/ml is noted, the patient is asked to bring the
treatment assistant to the next consultation, and begins a
cycle of adherence visits in which the pillbox is ﬁlled at
the clinic with the counsellor or clinician in attendance.
This is done weekly for 4 weeks. For the subsequent 8
weeks, the patient attends every 2 weeks and ﬁlls the
pillbox and receives an additional week’s treatment at
each visit. Any problems with adherence are explored
and individual support is provided. At the end of this
12-week period, the viral load test is repeated.
Methods
The study of clinical outcomes is a prospective open
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ART who initiated antiretroviral treatment at any of
the three health centres referred to above, between
May 2001 and the end of 2002. The cohort is ordered
and analysed by duration on treatment. Patients were
followed until their most recent visit before 31 July
2003.
Viral load suppression was deﬁned in this analysis as an
HIV-RNA measurement below 400 copies/ml. It was
calculated in an as-tested analysis at the durations after
starting ART when these tests are scheduled according
to the protocol, namely at 3, 6, 12, 18 and 24 months.
The Kaplan–Meier method was used to calculate the
cumulative proportion of patients who had achieved
undetectable viral loads. In a separate analysis, entry
was changed to the point of the ﬁrst undetectable viral
load, and the Kaplan–Meier method was used to
determine the cumulative proportion of patients with
viral rebound. Viral rebound was deﬁned as two
consecutive viral load levels above 400 copies/ml. The
median CD4 cell count on the initiation of ART was
calculated for the above cohort as well as for adults
beginning ART between the end of 2002 and 30
September 2003.
Loss to follow-up was deﬁned as exit from the cohort
with no information available on current status for a
duration of 3 months or longer in patients who had
not negotiated a transfer out of the programme.
Patients who underwent the structured adherence-
enhancing programme in response to a detectable viral
load were identiﬁed. The virological response to this
input is described as the proportion of patients with
repeat viral load measurements that were below 400
copies/ml.
Plasma HIV-RNA levels were measured using the
nucleic acid sequence-based ampliﬁcation procedure
Nuclisens HIV-1 QT assay (BioMerieux, Boxtel, the
Netherlands). Analyses were performed using STATA
software (version 8.0; Stata Corp., College Station,
TX, USA).
The Research Ethics Committee of the South African
Medical Association approved the protocol for this
project.
Results
Between May 2001 and December 2002 a total of 287
treatment-naive patients began ART. Table 1 sum-
marizes the characteristics of patients initiated on ART,
including baseline CD4 cell counts, viral load measure-
ments and the initial regimens on which they were
started. The median CD4 cell count on initiating ART
for the cohort was 43 cells/l. The cumulative prob-
ability of survival was 86.3% at 24 months, at which
duration on treatment the median CD4 cell count gain
was 288 cells/l. The viral load was suppressed in
89.2% of patients at 6 months on ART, but this
decreased to 84.2% at 12 months and 69.7% at 24
months (Fig. 1). Detailed outcomes from this cohort
have been reported elsewhere [5]. At the end of July
2003, one patient from the cohort was lost to follow-
up, three patients had moved to a different province,
six patients were still attending the service but had
stopped ART, whereas three patients had stopped
attending the services altogether but were known to be
in good health.
The probability of achieving viral load suppression
increased rapidly in the ﬁrst year on ART, with
cumulatively 93.0% [95% conﬁdence interval (CI)
88.9–95.9] of patients achieving this in the ﬁrst year.
All patients who had undetectable viral load measure-
ments achieved these levels in the ﬁrst year. If the
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Table 1. Summary of characteristics of cohort.
Baseline
Number starting ART 287
Women 201 (70%)
Median CD4 cell count (IQR) 43 (IQR 13–94) cells/l
Viral load (mean log10 copies/ml) 5.18 (SD 0.68)
Initial regimens Zidovudine/lamivudine/efavirenz (60%)
Zidovudine/lamivudine/nevirapine (38%)
Other (2%)
Follow-up
Duration of follow-up (all) 13.9 (IQR 9.2–18.1) months
Survival at 24 months 86.3 (95% CI 81.7–89.8)%
Median CD4 cell count gain at 24 months 288 (IQR 181–470) cells/l
Patient retention on 31 July 2003
Patients lost to follow-up 1
Transferred out 3
In care but stopped ART 6
Alive but no longer in care 3
ART, Antiretroviral therapy; CI, conﬁdence interval; IQR, interquartile range; SD, standard
deviation.
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the analysis for at least a year, 95.8% (92.8–98.5) had at
least one viral load measurement below 400 copies/ml.
Eleven out of 18 patients (61%) with raised viral load
measurements at 6 months’ duration of ART had
subsequent viral load suppression after the period of
adherence promotion. At one clinic where the standar-
dized approach to raised viral load measurements was
particularly well applied, 10 out of 12 patients who had
raised levels at 6 months’ duration on ART had levels
below 400 copies/ml at the next test. Only two out of
eight patients with raised HIV-RNA measurements at
12 months achieved viral suppression below this level
after the adherence intervention at the same clinic.
The cumulative probability of viral rebound (two con-
secutive viral load measurements above 400 copies/ml)
after achieving viral load suppression was 13.2% (95%
CI 8.1–21.2) at 18 months since the ﬁrst level below
400 copies/ml (Fig. 2). As this analysis only includes
the ﬁrst 2 years of the programme, there are no data
for this parameter beyond 18 months since the ﬁrst
undetectable viral load level. Twelve patients had
started second-line treatment by the end of July 2003
[Kaplan–Meier estimate at 24 months of 8.7% (95% CI
4.0–18.1)].
Discussion
These results demonstrate that a cohort of patients
initiated on ART in a resource-limited setting in a
developing country can be retained. The fact that only
one patient was lost to follow-up, and so few others
left care, is remarkable. In addition, a substantial
proportion of patients achieved suppression of viral
replication. This compares very favourably with other
data from developed and developing countries [2,3,6].
The excellent retention of patients could be related to
services being situated within the primary care setting
close to patients’ homes and family environment as well
as to the careful preparation of patients. As it is difﬁcult
to ascertain robust predictors of adherence [7,8], there
has been a move to concentrate on patient preparation
before the initiation of ART rather than the use of
non-clinical predictors of adherence or selection criter-
ia. A paradigm focused on preparation rather than
selection is better suited to the aggressive targets for the
scaling up of ART in countries with large epidemics
(such as in South Africa) [9], where the view of ART
as a very expensive rationed intervention is rapidly
changing.
With scaling up, the key challenge will be balancing
programme quality (and in particular adherence pro-
motion) against coverage. Already in Khayelitsha, we
have seen the backlog of patients requiring ART
diminish, reﬂected by the increasing median CD4 cell
count on initiation of treatment, from 43 cells/li n
the cohort from 2001 to the end of 2003, to 61 cells/
l in the 2003 cohort. The length of time in care
before starting ART has also decreased dramatically, as
well as the extent of pre-ART morbidity. Many more
patients than those currently on ART (670 anticipated
at end of 2003) should be on ART in Khayelitsha, and
the duration from testing to being on ART is likely to
shorten even further. The extent to which pre-ART
morbidity and duration in care have contributed to
adherence is difﬁcult to quantify, and the role of these
factors will be difﬁcult to discern from programmatic
changes as the numbers of patients on ART increase.
Continuity of care and the fact that patients see the
same team at each visit certainly promote adherence in
our opinion. This has implications for the large-scale
roll-out of antiretroviral agents in South Africa, as it
appears that continuity of care and knowledge of each
patient are important, and that it is better to have more
facilities with manageable patient numbers than a few
large referral facilities that struggle to keep track of
their patients. A challenge that is emerging is maintain-
ing a reasonably sized programme in which patient-
centred care and continuity of care are possible while
enrolment is ongoing and total patient numbers are
constantly increasing.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
P
r
o
p
o
r
t
i
o
n
 
w
i
t
h
 
H
I
V
 
R
N
A
l
e
v
e
l
s
 

4
0
0
 
c
o
p
i
e
s
/
m
l
0.00
0.20
0.40
0.60
0.80
1.00
On ART
Tested
287 254
227
3 6 12
244
231
Months on ART
165
158
72
68
18 24
34
33
0.88 0.89 0.84 0.75 0.70
Fig. 1. Prevalence of viral load results below 400 copies/ml
by duration on antiretroviral therapy. ART, Antiretroviral
therapy.
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Fig. 2. Cumulative proportion of patients with conﬁrmed
viral rebound (two consecutive viral load results above 400
copies/ml).
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groups. As the programme developed, it was found that
patients on ART for some time had different needs and
problems to those who had recently been initiated on
therapy. Separate support groups were therefore orga-
nized for these patients in an attempt to orientate the
support infrastructure to the needs of patients who have
been on ART for many months or years. Additional
research is needed to identify the optimal strategies to
promote long-term adherence and particularly to re-
spond to those patients who do not adhere to therapy.
Although the Khayelitsha programme is rooted in the
public sector primary care services, external resources
have been required to achieve the described levels of
adherence. Preliminary cost data from Khayelitsha sug-
gest that, in spite of the falling prices of antiretroviral
drugs [10], the costs of clinical care and programme
support are relatively modest compared with drugs and
laboratory tests. Given the huge threat to society posed
by HIV/AIDS, we need to advocate for these extra
resources to be invested in primary care services
generally.
Viral load measurements can be used as a marker of
adherence in the ﬁrst year on ART. The high propor-
tion of patients achieving viral load suppression after
adherence support in response to a raised level at 6
months’ duration on ART conﬁrms that raised levels
in this period are mostly caused by adherence-related
problems in a treatment-naive context. In programmes
in which viral load measurements are part of the
clinical protocol, a standardized health service response
to raised levels should be anticipated and planned for,
both in terms of adherence promotion and regimen
change. There is a trade-off between repeating the
level after 4 weeks in which adherence had been tightly
monitored, but the duration is sub-optimal to achieve
full suppression, and repeating the level after 3 months
when clinicians can be less certain that adherence issues
have not resurfaced. International advice on ART for
poor countries is unclear on the roll of viral load
measurements in those countries that can afford them
[11]. When only two regimens are available, there is a
temptation to rely on immunological failure as a trigger
for regimen switching, especially as regimens with less
cross-resistance emerge. As the price of technologies to
quantify viral load falls, it is important to recognize the
role of this technology both in adherence promotion
and in determining when to switch regimens.
The high proportion of patients with undetectable viral
loads in the ﬁrst year on treatment underpins the fact
that adherence rates comparable to those in rich
countries are achievable in resource-limited settings if
interventions are appropriately implemented through
public sector primary care services. Many issues are
emerging related to adherence promotion, and current
strategies will need to be re-evaluated in the context of
much larger programmes.
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